IN2012DN03312A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03312A IN2012DN03312A IN3312DEN2012A IN2012DN03312A IN 2012DN03312 A IN2012DN03312 A IN 2012DN03312A IN 3312DEN2012 A IN3312DEN2012 A IN 3312DEN2012A IN 2012DN03312 A IN2012DN03312 A IN 2012DN03312A
- Authority
- IN
- India
- Prior art keywords
- compounds
- relates
- present
- heteroarylcarbonyl
- arylcarbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
- C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25388909P | 2009-10-22 | 2009-10-22 | |
PCT/AU2010/001398 WO2011047432A1 (en) | 2009-10-22 | 2010-10-21 | Fused ring analogues of anti-fibrotic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN03312A true IN2012DN03312A (uk) | 2015-10-23 |
Family
ID=43899730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3312DEN2012 IN2012DN03312A (uk) | 2009-10-22 | 2010-10-21 |
Country Status (8)
Country | Link |
---|---|
US (2) | US9062076B2 (uk) |
EP (2) | EP2947073B1 (uk) |
JP (3) | JP5904944B2 (uk) |
CN (2) | CN105153188B (uk) |
HK (2) | HK1217480A1 (uk) |
IN (1) | IN2012DN03312A (uk) |
SG (1) | SG10201501272SA (uk) |
WO (1) | WO2011047432A1 (uk) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
DK2799427T3 (en) | 2006-07-05 | 2018-10-22 | Fibrotech Therapeutics Pty Ltd | Therapeutic compounds |
WO2010105243A1 (en) | 2009-03-13 | 2010-09-16 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
CA2758071C (en) | 2009-04-06 | 2018-01-09 | Agios Pharmaceuticals, Inc. | Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use |
IN2012DN00471A (uk) | 2009-06-29 | 2015-06-05 | Agios Pharmaceuticals Inc | |
EP2491145B1 (en) | 2009-10-21 | 2016-03-09 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
EP2947073B1 (en) | 2009-10-22 | 2019-04-03 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
DK2571874T3 (en) | 2010-05-17 | 2016-05-17 | Forum Pharmaceuticals Inc | A crystalline form of (R) -7-chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide hydrochloride monohydrate |
WO2012068612A1 (en) | 2010-11-24 | 2012-05-31 | Fibrotech Therapeutics Pty Ltd | Methods of treating eye diseases associated with inflammation and vascular proliferation |
JP5837091B2 (ja) | 2010-12-17 | 2015-12-24 | アジオス ファーマシューティカルズ, インコーポレイテッド | ピルビン酸キナーゼm2(pkm2)調節剤としての新規n−(4−(アゼチジン−1−カルボニル)フェニル)−(ヘテロ−)アリールスルホンアミド誘導体 |
ES2569712T3 (es) | 2010-12-21 | 2016-05-12 | Agios Pharmaceuticals, Inc. | Activadores de PKM2 bicíclicos |
TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
RU2675656C2 (ru) | 2011-05-03 | 2018-12-21 | Аджиос Фармасьютикалз, Инк. | Способы применения активаторов пируваткиназы |
AU2012250690B2 (en) | 2011-05-03 | 2017-06-08 | Agios Pharmaceuticals, Inc | Pyruvate kinase activators for use in therapy |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
NZ700928A (en) | 2012-04-24 | 2017-06-30 | Vertex Pharma | Dna-pk inhibitors |
CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
IN2014MN02562A (uk) * | 2012-06-27 | 2015-07-24 | 4Sc Discovery Gmbh | |
FR2994184B1 (fr) * | 2012-08-02 | 2017-12-08 | Biomerieux Sa | Procedes de fonctionalisation et reactifs utilises dans de tels procedes utilisant un anhydride aza-isatoique ou un de ses derives, molecules biologiques ainsi traitees et kits |
LT3527563T (lt) | 2013-03-12 | 2021-12-10 | Vertex Pharmaceuticals Incorporated | Dnr-pk inhibitoriai |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
EP3019480B1 (en) | 2013-07-11 | 2020-05-06 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
AR097279A1 (es) * | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
WO2015042053A1 (en) | 2013-09-17 | 2015-03-26 | Pharmakea, Inc. | Vinyl autotaxin inhibitor compounds |
EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
EA201690713A1 (ru) | 2013-10-04 | 2016-08-31 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PT3424920T (pt) | 2013-10-17 | 2020-07-07 | Vertex Pharma | Co-cristais de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida e derivados deuterados dos mesmos como inibidores de adn-pk |
NZ723859A (en) | 2014-03-14 | 2023-01-27 | Servier Lab | Pharmaceutical compositions of therapeutically active compounds and their uses |
CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
JP6728061B2 (ja) | 2014-05-05 | 2020-07-22 | リセラ・コーポレイションLycera Corporation | RORγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療 |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
CN104761506B (zh) * | 2015-04-10 | 2017-05-03 | 温州大学 | 一种2‑(1‑苯乙烯基)喹唑啉酮化合物及其合成方法 |
DK3307271T3 (da) | 2015-06-11 | 2023-10-09 | Agios Pharmaceuticals Inc | Fremgangsmåder til anvendelse af pyruvatkinase-aktivatorer |
NZ740616A (en) | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
WO2017066566A1 (en) | 2015-10-15 | 2017-04-20 | Agios Pharmaceuticals, Inc | Combination therapy for treating malignancies |
PT3362066T (pt) | 2015-10-15 | 2021-11-16 | Celgene Corp | Terapia de combinação para tratar malignidades |
CN105175416B (zh) * | 2015-10-20 | 2017-12-22 | 中国药科大学 | 一种新型的组蛋白去乙酰化酶抑制剂 |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
KR20190115451A (ko) | 2017-02-03 | 2019-10-11 | 세르타 테라퓨틱스 피티와이 엘티디. | 항-섬유성 화합물 |
GB201721961D0 (en) * | 2017-12-27 | 2018-02-07 | Bp Oil Int | Methods for preparing fuel additives |
US11858927B2 (en) | 2018-01-31 | 2024-01-02 | Heparegenix Gmbh | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
CN110483432A (zh) * | 2018-05-14 | 2019-11-22 | 中国科学院上海药物研究所 | 一类丙烯酸类化合物及其制备方法、药物组合物和用途 |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
EP3810139A1 (en) | 2018-06-21 | 2021-04-28 | HepaRegeniX GmbH | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
BR112020026003A2 (pt) | 2018-07-16 | 2021-03-23 | Heparegenix Gmbh | inibidores de proteína quinase para promover a regeneração do fígado ou reduzir ou prevenir a morte de hepatócitos |
WO2020132384A1 (en) | 2018-12-21 | 2020-06-25 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
CN109705140A (zh) * | 2019-01-08 | 2019-05-03 | 荆楚理工学院 | 一种吡啶并[2,3-d][1,3]噁嗪衍生物的合成方法 |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
AU2021300429A1 (en) | 2020-07-02 | 2023-02-16 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
CN114831977B (zh) * | 2021-02-02 | 2023-12-19 | 北京大学 | 苯甲酸类衍生物作为trpm2蛋白抑制剂的用途 |
TW202302589A (zh) | 2021-02-25 | 2023-01-16 | 美商英塞特公司 | 作為jak2 v617f抑制劑之螺環內醯胺 |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5640710B2 (uk) | 1973-01-18 | 1981-09-22 | ||
JPS5830302B2 (ja) | 1974-04-16 | 1983-06-28 | キツセイヤクヒンコウギヨウ カブシキガイシヤ | シンキホウコウゾクカルボンサンアミドユウドウタイ ノ セイゾウホウホウ |
GB1484413A (en) | 1974-04-18 | 1977-09-01 | Kissei Pharmaceutical | Aromatic amidocarboxylic acid derivatives |
JPS5848545B2 (ja) | 1974-04-18 | 1983-10-28 | キツセイヤクヒンコウギヨウ カブシキガイシヤ | シンキホウコウゾクカルボンサンアミドユウドウタイ ノ セイゾウホウホウ |
JPS511440A (ja) | 1974-04-18 | 1976-01-08 | Kissei Pharmaceutical | Shinkihokozokukarubonsanjudotai no seizohoho |
JPS5855138B2 (ja) * | 1975-12-31 | 1983-12-08 | キツセイヤクヒンコウギヨウ カブシキガイシヤ | ホウコウゾクカルボンサンアミドユウドウタイノセイゾウホウホウ |
JPS6019738B2 (ja) | 1978-03-20 | 1985-05-17 | 久光製薬株式会社 | 新規なアントラニル酸誘導体 |
JPS5576852A (en) | 1978-12-01 | 1980-06-10 | Hisamitsu Pharmaceut Co Inc | Novel derivative of anthranilic acid |
JPS5817186B2 (ja) | 1981-01-23 | 1983-04-05 | キツセイ薬品工業株式会社 | 新規芳香族カルボン酸誘導体の製造方法 |
US4587356A (en) | 1981-09-01 | 1986-05-06 | Kissei Pharmaceutical Co., Ltd. | Process for the production of nuclear substituted cinnamoylanthranilic acid derivatives |
JPS6019754A (ja) | 1983-07-14 | 1985-01-31 | Kissei Pharmaceut Co Ltd | 芳香族カルボン酸アミド誘導体の製造方法 |
JPS60152454A (ja) | 1984-01-18 | 1985-08-10 | Terumo Corp | アミド誘導体およびこれを有効成分として含有する5−リポキシゲナ−ゼ作用阻害剤 |
JPS6191163A (ja) * | 1984-10-08 | 1986-05-09 | Fujimoto Seiyaku Kk | アントラニル酸誘導体の製造方法 |
DE3505609A1 (de) | 1985-02-19 | 1986-08-21 | Merck Patent Gmbh, 6100 Darmstadt | Benzimidazolyl-pyridazinone |
JPS625966A (ja) * | 1985-07-03 | 1987-01-12 | Nippon Shinyaku Co Ltd | ベンズイミダゾ−ル誘導体 |
JPH0692353B2 (ja) | 1987-05-26 | 1994-11-16 | マルコ製薬株式会社 | 新規なアミノ安息香酸アミド誘導体およびその製造法 |
JPS6416755A (en) | 1987-06-23 | 1989-01-20 | Biogal Gyogyszergyar | Manufacture of n-(3',4'-dimethoxycinnamoyl)-aniline derivative |
JPH01287066A (ja) | 1988-05-13 | 1989-11-17 | Fujimoto Seiyaku Kk | 新規なアントラニル酸誘導体 |
JPH07116029B2 (ja) | 1989-04-04 | 1995-12-13 | キッセイ薬品工業株式会社 | トラニラスト水溶液製剤 |
WO1991012237A1 (fr) | 1990-02-08 | 1991-08-22 | Eisai Co., Ltd. | Derive de sulfonamide de benzene |
US5248825A (en) | 1990-09-20 | 1993-09-28 | Merrell Dow Pharmaceuticals Inc. | Calcium uptake inhibitors |
DE4115184A1 (de) | 1991-05-09 | 1992-11-12 | Bayer Ag | Benzothiophen-2-carboxamid-s,s-dioxide |
US5622977A (en) | 1992-12-23 | 1997-04-22 | Celltech Therapeutics Limited | Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same |
EP0657422B1 (en) | 1993-12-09 | 1998-06-10 | Ono Pharmaceutical Co., Ltd. | Naphthyloxyacetic acid derivatives as PGE2 agonists and antagonists |
US5665737B1 (en) * | 1994-10-12 | 1999-02-16 | Euro Celtique Sa | Substituted benzoxazoles |
PL319605A1 (en) | 1994-10-12 | 1997-08-18 | Euro Celtique Sa | Novel benzoxazoles |
JPH08113567A (ja) * | 1994-10-17 | 1996-05-07 | Sando Yakuhin Kk | フェニルエテニル誘導体及びこれを含有する5−リポキシゲナーゼ阻害剤 |
US6444694B1 (en) * | 1995-06-06 | 2002-09-03 | Wyeth | Styryl benzimidazole derivatives |
JPH08337523A (ja) | 1995-06-14 | 1996-12-24 | Taiho Yakuhin Kogyo Kk | 血管新生阻害剤 |
US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
EP0974350B1 (en) | 1996-02-07 | 2002-08-28 | Lead Chemical Company Ltd. | External preparation containing tranilast and process for producing the same |
KR19990082523A (ko) | 1996-02-15 | 1999-11-25 | 간자와 무츠와 | 혈관생성 억제제 |
JPH09278653A (ja) | 1996-04-05 | 1997-10-28 | Santen Pharmaceut Co Ltd | 網膜疾患治療剤 |
DE19624155A1 (de) | 1996-06-18 | 1998-01-08 | Hoechst Ag | Substituierte Benzoesäurederivate, Verfahren zu ihrer Herstellung und die Anwendung der Verbindungen zur Behandlung von Krankheiten |
GB9625913D0 (en) * | 1996-12-13 | 1997-01-29 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their seco precursors,and their use as prodrugs |
JPH10259129A (ja) | 1997-01-16 | 1998-09-29 | Kissei Pharmaceut Co Ltd | 血管新生阻害剤 |
FR2759368B1 (fr) | 1997-02-10 | 2001-06-01 | Galderma Rech Dermatologique | Composes biaromatiques, compositions les contenant et utilisations |
JPH10306024A (ja) | 1997-03-07 | 1998-11-17 | Kissei Pharmaceut Co Ltd | 糸球体疾患の予防および治療剤 |
TW591030B (en) * | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
JPH10330254A (ja) | 1997-04-01 | 1998-12-15 | Kissei Pharmaceut Co Ltd | 翼状片の進行および術後の再発抑制剤 |
US6127392A (en) | 1997-08-05 | 2000-10-03 | American Home Products Corporation | Anthranilic acid analogs |
JPH11180952A (ja) * | 1997-12-19 | 1999-07-06 | Maruho Co Ltd | 2−オキシインドール誘導体 |
JP3256513B2 (ja) * | 1998-02-11 | 2002-02-12 | ファイザー製薬株式会社 | ベンゾイミダゾールシクロオキシゲナーゼ−2阻害剤 |
EP1101758A4 (en) * | 1998-07-28 | 2002-04-03 | Nihon Nohyaku Co Ltd | DICARBOXYLIC DIAMIDE DERIVATIVES WITH CONDENSED HETEROCYCLE OR SALTS THEREOF, HERBICIDES AND THEIR USE |
EP1140896A1 (en) | 1998-12-21 | 2001-10-10 | Takeda Chemical Industries, Ltd. | Benzothiepin-anilide derivatives, their production and their use for antagonizing ccr-5 |
CN1361768A (zh) * | 1999-06-02 | 2002-07-31 | Nps药物有限公司 | 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途 |
DE19935219A1 (de) | 1999-07-27 | 2001-02-01 | Boehringer Ingelheim Pharma | Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
CN1373662A (zh) | 1999-08-12 | 2002-10-09 | 法玛西雅意大利公司 | 3(5)-氨基-吡唑衍生物、其制备方法及其用作抗肿瘤剂的用途 |
US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
WO2001074810A2 (en) * | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists |
GB0019950D0 (en) * | 2000-08-12 | 2000-09-27 | Smithkline Beecham Plc | Compounds |
WO2002030894A2 (en) * | 2000-09-19 | 2002-04-18 | Taiho Pharmaceutical Co., Ltd. | Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins |
WO2002055454A2 (en) | 2001-01-10 | 2002-07-18 | Smithkline Beecham Corporation | Process and product |
GB2372986A (en) * | 2001-01-17 | 2002-09-11 | Xenova Ltd | 2-oxo, 4-hydroxy pyrroles and quinolines |
ES2247298T3 (es) | 2001-01-23 | 2006-03-01 | Eli Lilly And Company | Derivados de piperazina y piperidina como agonistas del receptor de melanocortina. |
WO2002066454A1 (en) * | 2001-02-21 | 2002-08-29 | Sankyo Company, Limited | Chromene derivatives |
ATE479657T1 (de) | 2001-02-28 | 2010-09-15 | Univ Temple | N-(aryl)-2-arylethensulfonamide und ihre therapeutischen anwendungen |
AR034897A1 (es) * | 2001-08-07 | 2004-03-24 | Hoffmann La Roche | Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos |
US7429593B2 (en) | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
JP4851671B2 (ja) | 2001-10-11 | 2012-01-11 | ニチバン株式会社 | トラニラスト経皮吸収貼付剤およびその製造方法 |
TW200303742A (en) * | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
WO2003045929A1 (fr) * | 2001-11-26 | 2003-06-05 | Takeda Chemical Industries, Ltd. | Derive bicyclique, procede de production de ce derive et utilisation correspondante |
US6759428B2 (en) * | 2001-12-04 | 2004-07-06 | Roche Palo Alto Llc | Indole nitriles |
JP2005518371A (ja) | 2001-12-10 | 2005-06-23 | アムジエン・インコーポレーテツド | バニロイド受容体リガンド及び治療に於けるこれらの使用 |
TW200303302A (en) | 2001-12-19 | 2003-09-01 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
DE60231646D1 (de) * | 2001-12-19 | 2009-04-30 | Janssen Pharmaceutica Nv | Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren |
AU2002359922A1 (en) | 2001-12-27 | 2003-07-15 | Taisho Pharmaceutical Co., Ltd. | Carboxylic acid derivative |
WO2003059913A1 (en) | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Roh-kinase inhibitors |
JP2004143134A (ja) | 2002-02-13 | 2004-05-20 | Takeda Chem Ind Ltd | Jnk阻害剤 |
JP2004075614A (ja) * | 2002-08-20 | 2004-03-11 | Sankyo Co Ltd | クロメン誘導体を含有する医薬 |
US7196078B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
AU2003258491A1 (en) | 2002-09-05 | 2004-03-29 | Neurosearch A/S | Amide derivatives and their use as chloride channel blockers |
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
DE10254872A1 (de) | 2002-11-25 | 2004-06-03 | Symrise Gmbh & Co. Kg | Anthranilsäureamide und deren Derivate als kosmetische und pharmazeutische Wirkstoffe |
CN1506359A (zh) | 2002-12-05 | 2004-06-23 | �й�ҽѧ��ѧԺҩ���о��� | 新的香豆素酰胺衍生物及其制法和其药物组合物与用途 |
WO2004089415A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST |
AU2004234067B2 (en) * | 2003-04-30 | 2008-02-28 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
US7691870B2 (en) | 2003-07-11 | 2010-04-06 | Merck Patent Gmbh | Benzimidazole carboxamides as raf kinase inhibitors |
US20050026944A1 (en) | 2003-07-24 | 2005-02-03 | Patrick Betschmann | Thienopyridine and furopyridine kinase inhibitors |
US7250444B2 (en) | 2003-08-11 | 2007-07-31 | Pfizer Inc. | Pyrrole-based HMG-CoA reductase inhibitors |
GB0319126D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
CN101445469B (zh) * | 2003-09-24 | 2013-02-13 | 梅特希尔基因公司 | 组蛋白脱乙酰基酶抑制剂 |
US7868205B2 (en) | 2003-09-24 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
DE10346913A1 (de) | 2003-10-09 | 2005-05-04 | Merck Patent Gmbh | Acylhydrazonderivate |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
EA012414B1 (ru) | 2004-06-08 | 2009-10-30 | Темпл Юниверсити Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | Гетероарилсульфоны и сульфонамиды и их терапевтические применения |
WO2005123089A2 (en) | 2004-06-10 | 2005-12-29 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
AU2005267385B2 (en) | 2004-06-25 | 2011-11-10 | Janssen Pharmaceutica N.V. | Quaternary salt CCR2 antagonists |
DE102004030987A1 (de) | 2004-06-26 | 2006-01-12 | Merck Patent Gmbh | Ortho-substituierte (3-Hydroxyphenyl)-essigsäure-benzyliden-hydrazide |
US7671077B2 (en) | 2004-07-19 | 2010-03-02 | Leu-Fen Hou Lin | Neuroprotective small organic molecules, compositions and uses related thereto |
US8188277B2 (en) | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
CN101056635A (zh) | 2004-11-04 | 2007-10-17 | 默克公司 | 烟酸受体激动剂、含有该化合物的组合物及治疗方法 |
KR20070102670A (ko) | 2004-11-17 | 2007-10-19 | 앤지오젠 파마슈티칼스 피티와이. 리미티드 | B 세포 기능 조절방법 |
WO2006057922A2 (en) | 2004-11-23 | 2006-06-01 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
ITMI20050261A1 (it) | 2005-02-21 | 2006-08-22 | Carlo Ghisalberti | Analoghi strutturali di avenatramidi loro uso in composizioni utili nel trattamento di disordini dermatologici |
US7998974B2 (en) * | 2005-03-03 | 2011-08-16 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
CA2602583A1 (en) | 2005-03-24 | 2006-09-28 | Janssen Pharmaceutica N.V. | Biaryl derived amide modulators of vanilloid vr1 receptor |
CA2602467C (en) * | 2005-03-30 | 2014-09-02 | Kabushiki Kaisha Yakult Honsha | Bcrp/abcg2 inhibitor |
ITMI20050674A1 (it) | 2005-04-15 | 2006-10-16 | Univ Degli Studi Milano | Uso di derivati ammidici come agenti modificatori del gusto composizioni aromatizzanti e prodotti che li contengono |
RU2007145434A (ru) * | 2005-05-10 | 2009-06-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Бициклические производные в качестве модуляторов ионных каналов |
CA2609059A1 (en) | 2005-05-16 | 2006-11-23 | Angiogen Pharmaceuticals Pty. Ltd. | Methods and compositions for the treatment of pain |
WO2006134013A1 (en) | 2005-06-14 | 2006-12-21 | Symrise Gmbh & Co. Kg | Mixtures comprising anthranilic acid amides and cooling agents as cosmetic and pharmaceutical compositions for alleviating itching |
WO2007015744A1 (en) | 2005-07-21 | 2007-02-08 | Incyte Corporation | Disubstituted thienyl compounds and their use as pharmaceuticals |
US8911795B2 (en) | 2005-11-30 | 2014-12-16 | Symrise Ag | Compositions comprising dihydroavenanthramide D and climbazole as cosmetic and pharmaceutical compositions for alleviating itching |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
AU2007234843B2 (en) * | 2006-04-07 | 2013-07-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US20070286892A1 (en) | 2006-06-13 | 2007-12-13 | Uri Herzberg | Compositions and methods for preventing or reducing postoperative ileus and gastric stasis in mammals |
ES2462925T3 (es) | 2006-06-14 | 2014-05-26 | Symrise Ag | Compuestos con efecto antimicrobiano para el tratamiento de fetidez oral |
EP2035405A1 (de) | 2006-07-05 | 2009-03-18 | Merck Patent GmbH | Sulfamat-benzothiophen-derivate |
DK2799427T3 (en) | 2006-07-05 | 2018-10-22 | Fibrotech Therapeutics Pty Ltd | Therapeutic compounds |
KR100832747B1 (ko) | 2006-10-27 | 2008-05-27 | 한국화학연구원 | 아미노피라졸 유도체, 이의 제조 방법 및 이를 함유하는허혈성 질환의 예방 또는 치료용 조성물 |
EP2089355A2 (en) | 2006-11-01 | 2009-08-19 | Brystol-Myers Squibb Company | Modulators of glucocorticoid receptor, ap-1, and/or nf- kappa b activity and use thereof |
CA2668190A1 (en) * | 2006-11-03 | 2008-05-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2008073461A2 (en) | 2006-12-11 | 2008-06-19 | Wyeth | Ion channel modulators |
PE20081581A1 (es) | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
WO2008109238A1 (en) | 2007-03-02 | 2008-09-12 | Janssen Pharmaceutica N.V. | Substituted cyclopentyl piperidine ccr2 antagonists |
EP1972624A1 (en) | 2007-03-23 | 2008-09-24 | Clariant International Ltd. | Benzoxazinones and their use as ultraviolet light absorbers |
US20090239982A1 (en) | 2007-03-30 | 2009-09-24 | Fujifilm Corporation | Ultraviolet Absorbent and Heterocyclic Compound |
EP2155744A1 (en) | 2007-04-10 | 2010-02-24 | Lundbeck, H., A/S | Heteroaryl amide analogues as p2x7 antagonists |
CA2690410C (en) * | 2007-06-12 | 2015-09-29 | Provid Pharmaceuticals, Inc. | Kinase inhibitors, compositions thereof, and methods of use therewith |
WO2009006577A2 (en) * | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
EP2030617A1 (en) | 2007-08-17 | 2009-03-04 | Sygnis Bioscience GmbH & Co. KG | Use of tranilast and derivatives thereof for the therapy of neurological conditions |
CA2699157A1 (en) | 2007-09-10 | 2009-03-19 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
TWI440638B (zh) | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
US20090170842A1 (en) * | 2007-11-14 | 2009-07-02 | University Of Kansas | Brca1-based breast or ovarian cancer prevention agents and methods of use |
EP2225214A1 (en) | 2007-11-28 | 2010-09-08 | NeuroSearch AS | Novel phenyl-acetamide and phenyl-propionamide derivatives useful as potassium channel modulators |
EP2234486A4 (en) * | 2007-12-19 | 2011-09-14 | Scripps Research Inst | BENZIMIDAZOLE AND ANALOGUE AS RHO-KINASEHEMMER |
US20090163586A1 (en) | 2007-12-20 | 2009-06-25 | Astrazeneca Ab | Bis-(Sulfonylamino) Derivatives in Therapy 205 |
KR20160017139A (ko) | 2007-12-21 | 2016-02-15 | 피브로테크 세라퓨틱 피티와이 엘티디 | 항섬유증 제제의 할로겐화 유사체 |
CN101481323B (zh) | 2008-01-11 | 2013-11-20 | 中国人民解放军军事医学科学院毒物药物研究所 | 苯并环庚烯类衍生物、其制备方法及医药用途 |
TWI392673B (zh) | 2008-08-27 | 2013-04-11 | Calcimedica Inc | 調控細胞內鈣離子濃度之化合物 |
EP2179984A1 (en) | 2008-10-27 | 2010-04-28 | Congenia S.r.l. | Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition |
CN101423503A (zh) * | 2008-12-04 | 2009-05-06 | 上海大学 | 2-(反式-2,3-二氢-2-芳基-1-氰基-3-甲氧羰基环丙烷)-1,3-苯并噻唑及其合成方法 |
WO2010103130A2 (en) | 2009-03-13 | 2010-09-16 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Novel bicyclic heterocycles |
EP2947073B1 (en) | 2009-10-22 | 2019-04-03 | Fibrotech Therapeutics Pty Ltd | Fused ring analogues of anti-fibrotic agents |
-
2010
- 2010-10-21 EP EP15169791.9A patent/EP2947073B1/en not_active Not-in-force
- 2010-10-21 JP JP2012534495A patent/JP5904944B2/ja not_active Expired - Fee Related
- 2010-10-21 SG SG10201501272SA patent/SG10201501272SA/en unknown
- 2010-10-21 WO PCT/AU2010/001398 patent/WO2011047432A1/en active Application Filing
- 2010-10-21 EP EP10824314.8A patent/EP2491030B1/en not_active Not-in-force
- 2010-10-21 US US13/503,160 patent/US9062076B2/en not_active Expired - Fee Related
- 2010-10-21 IN IN3312DEN2012 patent/IN2012DN03312A/en unknown
- 2010-10-21 CN CN201510259423.XA patent/CN105153188B/zh not_active Expired - Fee Related
- 2010-10-21 CN CN201080047294.3A patent/CN102574843B/zh not_active Expired - Fee Related
-
2015
- 2015-06-04 US US14/730,753 patent/US9951087B2/en active Active
- 2015-10-15 JP JP2015203785A patent/JP6215890B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-10 HK HK16105337.3A patent/HK1217480A1/zh not_active IP Right Cessation
- 2016-05-26 HK HK16106007.0A patent/HK1217951A1/zh not_active IP Right Cessation
-
2017
- 2017-07-28 JP JP2017146253A patent/JP6437060B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP6437060B2 (ja) | 2018-12-12 |
JP5904944B2 (ja) | 2016-04-20 |
EP2491030B1 (en) | 2015-07-15 |
CN105153188A (zh) | 2015-12-16 |
HK1217951A1 (zh) | 2017-01-27 |
EP2947073A2 (en) | 2015-11-25 |
EP2947073A3 (en) | 2016-02-17 |
JP6215890B2 (ja) | 2017-10-18 |
EP2491030A4 (en) | 2013-04-17 |
US9062076B2 (en) | 2015-06-23 |
WO2011047432A1 (en) | 2011-04-28 |
JP2016128401A (ja) | 2016-07-14 |
CN105153188B (zh) | 2018-06-01 |
US9951087B2 (en) | 2018-04-24 |
US20120270863A1 (en) | 2012-10-25 |
EP2947073B1 (en) | 2019-04-03 |
CN102574843B (zh) | 2015-06-17 |
JP2013508306A (ja) | 2013-03-07 |
CN102574843A (zh) | 2012-07-11 |
EP2491030A1 (en) | 2012-08-29 |
HK1217480A1 (zh) | 2017-01-13 |
US20130338151A9 (en) | 2013-12-19 |
US20150266893A1 (en) | 2015-09-24 |
JP2018012700A (ja) | 2018-01-25 |
SG10201501272SA (en) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN03312A (uk) | ||
IN2014DN10386A (uk) | ||
GB201118656D0 (en) | New compounds | |
WO2012174487A3 (en) | Bromodomain inhibitors and uses thereof | |
WO2012151512A3 (en) | Bromodomain inhibitors and uses thereof | |
PH12015500724B1 (en) | 1, 2, 4-triazine derivatives for the treatment of viral infections | |
MX345535B (es) | Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso. | |
PH12014501967A1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
MY165826A (en) | Pharmaceutical composition | |
MX2013001677A (es) | Formulaciones estables de linaclotida. | |
MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
MX2011013032A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
MX342947B (es) | Tratamiento de diabetes tipo 2. | |
MX357284B (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
MX2013002118A (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
IN2012DN00239A (uk) | ||
MX2015000179A (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
WO2013038200A3 (en) | Neurodevelopmental disorders | |
IN2013MU01240A (uk) | ||
IN2013MU01241A (uk) | ||
IN2013MU01242A (uk) | ||
IN2013MU02059A (uk) | ||
IN2013MU01245A (uk) | ||
IN2013MU01247A (uk) | ||
IN2013MU01250A (uk) |